Soluble Receptor for Advanced Glycation End Products for Therapeutic Application
用于治疗应用的高级糖基化终产物的可溶性受体
基本信息
- 批准号:8552494
- 负责人:
- 金额:$ 12.3万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:
- 资助国家:美国
- 起止时间:至
- 项目状态:未结题
- 来源:
- 关键词:Advanced Glycosylation End ProductsAdvertisingAffinity ChromatographyAlgorithmsAlzheimer&aposs DiseaseAmino Acid SequenceAnimal ModelAnimalsAnti-Inflammatory AgentsAnti-inflammatoryAtherosclerosisAwardBasic ScienceBiochemicalBlood VesselsCardiovascular DiseasesCell LineCell surfaceChemistryChinese Hamster Ovary CellCleaved cellClinicClinical TrialsCodon NucleotidesComplementary DNADataDetectionDevelopmentDiabetes MellitusDiseaseDoseDrug Delivery SystemsEpitopesExhibitsFutureGenetic EngineeringGoalsGuanine + Cytosine CompositionIn VitroInfarctionInflammationInflammatoryInflammatory ResponseInjuryLaboratoriesLegal patentManuscriptsMediatingMembrane ProteinsMolecularMolecular BiologyPeptide Sequence DeterminationPharmaceutical PreparationsPhysiologyPolysaccharidesPost-Translational Protein ProcessingProcessProductionPropertyRNA Splice SitesRNA SplicingReportingSignal TransductionStagingStructureSystemTestingTherapeuticUnited States National Institutes of HealthVascular DiseasesVascular Endothelial Cellatherogenesisbaseclinical applicationcombatexperiencein vivomonocytenanoparticleneointima formationparticlepre-clinicalpreventreceptorresearch and developmentrestenosisscale uptool
项目摘要
Cellular signaling via receptor for advanced glycation end products (RAGE) results in pro-inflammatory responses. RAGE-mediated inflammation has been implicated in inflammatory diseases including diabetes, atherosclerosis, and Alzheimers disease. The spliced or proteolytically cleaved form of RAGE is referred as soluble RAGE (sRAGE), which functions as a natural decoy counter-effecting RAGE signaling. It has been demonstrated in animal models that administration of sRAGE blocks atherogenesis, and stabilizes existing plaques on the vessel wall. In addition, sRAGE also prevents the formation of neointima prompted by vascular injuries and hence inhibits restenosis.
We have developed Chinese Hamster Ovary (CHO) cell lines that stably express sRAGE, and the accompanied affinity purification strategies that produce homogenous sRAGE. Systemic studies of sRAGE application in restenosis animal models have been completed, and data have been analyzed. Our results showed that sRAGE produced in our laboratory exhibits 1000 x higher potency than that of previously reported. In addition to blocking restenosis, we also tested sRAGE blockage on infarct animal models and obtained promising preliminary results. We also performed studies to explore the molecular basis of the observed high potency of sRAGE and found that N-glycan structure in sRAGE contributes to its bioactivity.
To further develop sRAGE as an effective therapeutic product, we used GeneOptimizer algorithm from Invitrogen to optimize T7-sRAGE----this tool removes sequence repeat, killer motifs, splice sites and RNA secondary structures in the cDNA sequence and optimize codon usage (for CHO cell) and GC content without changing protein sequence. We plan to test whether the new sRAGE cDNA has a higher level of expression and compare to native sequence. This step should enhance future sRAGE scale-up production.
To overcome technical hurdles for expression and detection of sRAGE, we also developed a set of expression modules that facilitate subcloning, cell-surface expression. and epitope tagging of mammalian membrane proteins. U.S. Provisional Patent (No. 61/142,531) has been awarded to this invention, and NIH is currently advertising the invention. R&D Status: Pre-clinical in vitro.
通过晚期糖基化终末产物 (RAGE) 受体的细胞信号传导导致促炎症反应。 RAGE 介导的炎症与糖尿病、动脉粥样硬化和阿尔茨海默病等炎症性疾病有关。 RAGE 的剪接或蛋白水解形式被称为可溶性 RAGE (sRAGE),其功能是对抗 RAGE 信号传导的天然诱饵。动物模型已证明,给予 sRAGE 可阻止动脉粥样硬化形成,并稳定血管壁上现有的斑块。此外,sRAGE 还可以防止血管损伤引起的新内膜形成,从而抑制再狭窄。
我们开发了稳定表达 sRAGE 的中国仓鼠卵巢 (CHO) 细胞系,以及产生同质 sRAGE 的亲和纯化策略。 sRAGE在再狭窄动物模型中应用的系统研究已经完成,并对数据进行了分析。我们的结果表明,我们实验室生产的 sRAGE 的效力比之前报道的高出 1000 倍。除了阻断再狭窄之外,我们还在梗塞动物模型上测试了 sRAGE 阻断作用,并获得了有希望的初步结果。我们还进行了研究来探索所观察到的 sRAGE 高效力的分子基础,并发现 sRAGE 中的 N-聚糖结构有助于其生物活性。
为了进一步将 sRAGE 开发为有效的治疗产品,我们使用 Invitrogen 的 GeneOptimizer 算法来优化 T7-sRAGE——该工具去除 cDNA 序列中的序列重复、杀手基序、剪接位点和 RNA 二级结构,并优化密码子使用(对于 CHO 细胞)和 GC 含量,而不改变蛋白质序列。我们计划测试新的 sRAGE cDNA 是否具有更高的表达水平,并与天然序列进行比较。这一步骤将促进未来 sRAGE 的规模化生产。
为了克服 sRAGE 表达和检测的技术障碍,我们还开发了一套促进亚克隆、细胞表面表达的表达模块。和哺乳动物膜蛋白的表位标记。这项发明已获得美国临时专利(No. 61/142,531),NIH 目前正在对这项发明进行广告宣传。研发状态:体外临床前。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Edward Lakatta其他文献
Edward Lakatta的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Edward Lakatta', 18)}}的其他基金
Therapeutic Potential of EPO and its Derivatives for Reducing Blood Pressure
EPO 及其衍生物降低血压的治疗潜力
- 批准号:
9147229 - 财政年份:
- 资助金额:
$ 12.3万 - 项目类别:
Effects Of Age And Conditioning Status On Rest And Exercise Cardiac Performance
年龄和体能状态对休息和运动心脏功能的影响
- 批准号:
8931601 - 财政年份:
- 资助金额:
$ 12.3万 - 项目类别:
Matching ATP supply and demand in cardiac pacemaker cells
匹配心脏起搏细胞中的 ATP 供应和需求
- 批准号:
8931611 - 财政年份:
- 资助金额:
$ 12.3万 - 项目类别:
PDE3, PDE4 and PKC regulate local Ca2+ releases and cardiac pacemaker firing
PDE3、PDE4 和 PKC 调节局部 Ca2 释放和心脏起搏器放电
- 批准号:
8736511 - 财政年份:
- 资助金额:
$ 12.3万 - 项目类别:
Age-Associated Changes in Arterial Proteome and Aortic Smooth Muscle Signaling
动脉蛋白质组和主动脉平滑肌信号与年龄相关的变化
- 批准号:
8931487 - 财政年份:
- 资助金额:
$ 12.3万 - 项目类别:
相似国自然基金
小型类人猿合唱节奏的功能假说——宣
示社会关系(Social bond
advertising) ——验证研究
- 批准号:
- 批准年份:2025
- 资助金额:10.0 万元
- 项目类别:省市级项目
相似海外基金
SaTC: CORE: Medium: Increasing user autonomy and advertiser and platform responsibility in online advertising
SaTC:核心:中:增加在线广告中的用户自主权以及广告商和平台责任
- 批准号:
2318290 - 财政年份:2024
- 资助金额:
$ 12.3万 - 项目类别:
Continuing Grant
Marketing meaninglessness: critical anthropology of transnational advertising agencies
营销无意义:跨国广告公司的批判人类学
- 批准号:
2724869 - 财政年份:2024
- 资助金额:
$ 12.3万 - 项目类别:
Studentship
Innovation in Manufacturing to benefit the Marketing & Advertising Industry
制造创新有利于营销
- 批准号:
10064566 - 财政年份:2023
- 资助金额:
$ 12.3万 - 项目类别:
Collaborative R&D
Collaborative Research: SaTC: CORE: Medium: Understanding and Combatting Impersonation Attacks and Data Leakage in Online Advertising
协作研究:SaTC:核心:媒介:理解和打击在线广告中的冒充攻击和数据泄露
- 批准号:
2247516 - 财政年份:2023
- 资助金额:
$ 12.3万 - 项目类别:
Continuing Grant
The Impact of Programmatic Advertising on Market Competition
程序化广告对市场竞争的影响
- 批准号:
23K18786 - 财政年份:2023
- 资助金额:
$ 12.3万 - 项目类别:
Grant-in-Aid for Research Activity Start-up
A Dynamic Analysis of Advertising Interactive Techniques to Gain the Consumer Engagement
获得消费者参与的广告互动技术的动态分析
- 批准号:
23K01642 - 财政年份:2023
- 资助金额:
$ 12.3万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Enabling profitable digital advertising for British SMEs with AI-powered multichannel ads brokerage service
通过人工智能驱动的多渠道广告经纪服务,为英国中小企业实现盈利的数字广告
- 批准号:
10070962 - 财政年份:2023
- 资助金额:
$ 12.3万 - 项目类别:
Collaborative R&D
Cross-Platform Advertising Accountability
跨平台广告责任
- 批准号:
10071299 - 财政年份:2023
- 资助金额:
$ 12.3万 - 项目类别:
Collaborative R&D
Improving the accountability of dark advertising on digital platforms
提高数字平台上暗广告的问责制
- 批准号:
IE230100647 - 财政年份:2023
- 资助金额:
$ 12.3万 - 项目类别:
Early Career Industry Fellowships
An AI/ML-powered insight and improvement tool to help bricks and mortar Mission-Led Business (MLBs) to improve advertising, marketing and business performance
一款由 AI/ML 驱动的洞察和改进工具,可帮助实体任务主导型企业 (MLB) 改善广告、营销和业务绩效
- 批准号:
10067255 - 财政年份:2023
- 资助金额:
$ 12.3万 - 项目类别:
Collaborative R&D














{{item.name}}会员




